Bulevirtide shows promise for the treatment of the hepatitis D virus. In a clinical trial, patients with chronic hepatitis D infection, with or without cirrhosis, were given either 2 mg or 10 mg of bulevirtide daily for 144 weeks. After 48 weeks of treatment, 45% of patients on the 2 mg dose and 48% on the 10 mg dose achieved a combined response of undetectable hepatitis D virus and normal liver enzyme levels, compared to only 2% of control patients. Among the treated patients, 12% on the 2 mg dose and 20% on the 10 mg dose had undetectable virus levels. The most common side effects with bulevirtide were headache, itching, and fatigue, and they occurred more frequently with bulevirtide than with the control.

To know more: About the original article click here.